Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines

British Journal of Dermatology

Volumn 162, Issue 2, 2010, Pages 371-379

  Han, S S ^a   Lee, M ^a   Park, G H ^a,b   Bang, S H ^c   Kang, Y K ^a   Kim, T W ^a   Lee, J L ^a   Chang, H M ^a   Ryu, M H ^a  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Institute for Life Sciences   (South Korea)

Author keywords

Cetuximab; Epidermal growth factor; Papulopustular eruption; Xerosis

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FILAGGRIN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INVOLUCRIN; LORICRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HAIR FOLLICLE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LASER MICROSCOPY; MALE; PAPULOPUSTULAR ERUPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; SKIN BIOPSY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DRUG ERUPTIONS; EPIDERMAL GROWTH FACTOR; EPIDERMIS; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1ALPHA; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74349101443     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09536.x     Document Type: Article

References (36)

1. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004 90 : 566 572.
2. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000 10 : 505 510.
3. Nanney LB, Stoscheck CM, King LE Jr. et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990 94 : 742 748.
4. Kari C, Chan TO, Rocha de Quadros M et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003 63 : 1 5.
5. Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995 269 : 230 234.
6. Mimeault M, Bonenfant D, Batra SK. New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 2004 17 : 153 166.
7. Pasonen-Seppanen S, Karvinen S, Torronen K et al. EGF upregulates, whereas TGF-beta downregulates, the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. J Invest Dermatol 2003 120 : 1038 1044.
8. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997 109 : 751 756.
9. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002 20 : 4292 4302. (Pubitemid 35266289)
10. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002 20 : 110 124.
11. Hauser PJ, Agrawal D, Hackney J et al. STAT3 activation accompanies keratinocyte differentiation. Cell Growth Differ 1998 9 : 847 855.
12. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001 144 : 1169 1176.
13. Sayama K, Hanakawa Y, Shirakata Y et al. Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation. J Biol Chem 2001 276 : 999 1004.
14. Stoll SW, Benedict M, Mitra R et al. EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL. Oncogene 1998 16 : 1493 1499.
15. Wakugawa M, Nakamura K, Akatsuka M et al. Interferon-gamma-induced RANTES production by human keratinocytes is enhanced by IL-1beta, TNF-alpha, IL-4 and IL-13 and is inhibited by dexamethasone and tacrolimus. Dermatology 2001 202 : 239 245.
16. Wei L, Debets R, Hegmans JJ et al. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 1999 187 : 358 364.
17. Cunliffe WJ, Holland DB, Clark SM et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000 142 : 1084 1091.
18. Jeremy AH, Holland DB, Roberts SG et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003 121 : 20 7.
19. Layton AM, Morris C, Cunliffe WJ et al. Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Exp Dermatol 1998 7 : 191 197.
20. Mitra SS, Simcock R. Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 2006 24 : e28 9.
21. Sanz A, del Valle ML. A man whose scapula was spared a drug-associated rash. CMAJ 2005 172 : 745.
22. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003 21 : 2237 2246.
23. Guy R, Kealey T. The effects of inflammatory cytokines on the isolated human sebaceous infundibulum. J Invest Dermatol 1998 110 : 410 415.
24. Van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002 147 : 598 601.
25. Graves JE, Jones BF, Lind AC et al. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 2006 55 : 349 353.
26. Mikami F, Gu H, Jono H et al. Epidermal growth factor receptor acts as a negative regulator for bacterium nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via an Src-dependent p38 mitogen-activated protein kinase signaling pathway. J Biol Chem 2005 280 : 36185 36194.
27. Takeuchi O, Takeda K, Hoshino K et al. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol 2000 12 : 113 117.
28. Takeuchi O, Hoshino K, Kawai T et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999 11 : 443 451.
29. Jugeau S, Tenaud I, Knol AC et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005 153 : 1105 1113.
30. Walon L, Gilbeau C, Lachapelle JM. Acneiform eruptions induced by cetuximab. Ann Dermatol Venereol 2003 130 : 443 446.
31. Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004 29 : 138 140.
32. Shah NT, Kris MG, Pao W et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005 23 : 165 174.
33. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004 84 : 23 6.
34. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002 138 : 129 131.
35. Malik SN, Siu LL, Rowinsky EK et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003 9 : 2478 2486.
36. Miettinen PJ, Berger JE, Meneses J et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995 376 : 337 341.